Imagine a world where breathing is a luxury and a cough marks the sound of an inner battle. Interstitial lung disease (ILD), a condition characterized by inflammation and fibrosis, is a major cause of severe respiratory illness and can occur in children. While researchers have made progress in slowing the disease in adults, the situation for children remains grim: there are currently no effective treatments, and lung transplantation is their only hope for survival.
The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agreement
Ferrer Secures Distribution Rights for Treprostinil, Targets IPF and PPF miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agreement with United Therapeutics Corporation for Tyvaso a pharmaceutical drugdevice combination product authorized for the treatment of WHO Group 3 Pulmonary Hypertension associated with Interstitial Lung Disease PHILD and for WHO Group 1 Pulmonary Arterial Hypertension PAH.
Press release - DelveInsight Business Research LLP - Graft Versus Host Disease Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) - published on openPR.com